Nick Ertl > Elkington + Fife LLP > Sevenoaks, England > Lawyer Profile

Elkington + Fife LLP
Nick Ertl photo

Work Department

UK and European patent attorney




Nick has 20 years experience in the drafting of patent applications and their prosecution around the world, especially before the EPO. He is entrusted by numerous large multinational corporations to prepare patent applications in the fields of semiconductor electronics, general electronics hardware, optical components and systems. Nick is always excited to work in areas of technology new to him, and to invest his own time to become familiar with the underlying science involved. As a result, he has worked in many diverse areas of technology over the years. Specialist technical fields include: audio-visual technology; communications; electrical devices and electronics; mechanical engineering; semiconductors. Areas of expertise include: filing and prosecution; freedom to operate opinions; patent drafting; validity and infringement opinions.


English, French


University of Nottingham (M.Eng).

Lawyer Rankings

London > TMT (technology, media and telecoms) > PATMA: Patent attorneys

Elkington + Fife LLP has demonstrable expertise in EPO opposition and appeals work, and it offers its pharmaceutical clients support with the entire lifecycle of their patent mandates; the group represents four of the largest pharmaceutical companies in the world. London-based senior partner Richard Gillard, praised as ‘tenacious and knowledgeable’, sits at the helm of the chemistry and life sciences practice with strong experience in opposition and appeals work and, while Nick Ertl in Sevenoaks chairs the electrical and mechanical group. Ertl is skilled in patent drafting for corporate clients, including for medical imaging, display technology, electronic circuits, optical communications equipment, and many more products. James Anderson (Sevenoaks) is highly adept at advising clients on mechanical, materials, and engineering patents, and London-based Jens Grabenstein is growing the firm’s biotechnology offering.